MiMedx Group (NASDAQ:MDXG) Announces Earnings Results

Key Points

• MiMedx reported a third-quarter loss of $0.01 per share and revenue of $62.28 million, below analyst expectations of $68.56 million. Total sales fell 45% year over year, primarily because wound-care revenue declined 71% following Medicare reimbursement changes.
• Surgical revenue increased 9% year over year, while cost reductions lifted gross margin to 80% and returned the company to positive adjusted EBITDA of $2 million. MiMedx ended the quarter with $121 million in net cash and no debt.
• The FTC’s second information request delayed MiMedx’s planned $300 million acquisition of Sanara MedTech, though management remains committed to the deal. MiMedx also reached a $25 million patent settlement and received a favorable court ruling involving AXIOFILL.

MiMedx Group (NASDAQ:MDXG - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.01) EPS for the quarter, FiscalAI reports. The company had revenue of $62.28 million for the quarter, compared to analyst estimates of $68.56 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%.

Here are the key takeaways from MiMedx Group's conference call:

• Surgical revenue grew 9% year over year, with volume increasing in the mid-teens and broad-based growth across placental sheets, particulates, and newer products. Management expects high-single-digit surgical growth in the fourth quarter.
• Total third-quarter sales fell 45% to $62 million, driven by a 71% decline in wound-care revenue following Medicare reimbursement changes. Although wound-care-center volume rose 7% sequentially, management said the market remains difficult to forecast and expects 2027 conditions to resemble 2026.
• Cost reductions and manufacturing improvements helped gross margin improve to 80% and returned the company to positive Adjusted EBITDA of $2 million, a roughly $10 million sequential improvement. Management expects further sequential EBITDA improvement in the fourth quarter and ended the period with $121 million in net cash and no debt.
• MiMedx reached a $25 million patent settlement and licensing agreement, while a federal court vacated the FDA’s adverse classification of AXIOFILL and remanded the matter for further consideration. Two additional patent cases remain active, with management citing favorable claim-construction rulings.
• The FTC issued a second request for information regarding the Sanara MedTech acquisition, delaying the closing timeline and triggering a ticking fee on MiMedx’s proposed $300 million acquisition financing. Management remains committed to the transaction, which it expects would add more than $100 million of revenue, at least $20 million in annual synergies, and an Adjusted EBITDA margin above 20%, but no closing date was provided.

MiMedx Group Trading Up 1.3%

Shares of MDXG stock traded up $0.05 during mid-day trading on Wednesday, hitting $3.95. 1,257,161 shares of the company's stock were exchanged, compared to its average volume of 1,296,922. MiMedx Group has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The stock has a 50-day simple moving average of $4.51 and a two-hundred day simple moving average of $4.33. The company has a quick ratio of 4.79, a current ratio of 5.33 and a debt-to-equity ratio of 0.07. The stock has a market cap of $575.75 million, a price-to-earnings ratio of 98.77 and a beta of 1.18.

Analyst Upgrades and Downgrades

MDXG has been the topic of a number of analyst reports. Raymond James Financial set a $8.00 price objective on MiMedx Group in a research note on Monday, August 17th. Weiss Ratings raised shares of MiMedx Group from a "sell (d)" rating to a "sell (d+)" rating in a research note on Thursday, August 27th. Wall Street Zen raised shares of MiMedx Group from a "sell" rating to a "hold" rating in a research note on Saturday, August 29th. Seaport Research Partners lowered shares of MiMedx Group to a "neutral" rating in a report on Monday, August 17th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of MiMedx Group in a research note on Tuesday, September 15th. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, MiMedx Group presently has an average rating of "Moderate Buy" and an average price target of $8.57.

MiMedx Group Company Profile

MiMedx Group, Inc NASDAQ: MDXG is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company's products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx's portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.